Stock CURE BIOCURE TECHNOLOGY INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biocure Technology Inc.

Equities

CURE

CA09075T1075

Uranium

Market Closed - Canadian Securities Exchange
Other stock markets
 09:30:00 2023-09-11 am EDT 		5-day change 1st Jan Change
0.015 CAD -25.00% Intraday chart for Biocure Technology Inc. -.--% -.--%
2023 Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Atriva Therapeutics GmbH announced that it expects to receive $15 million in funding CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 30.35 46.46 20.84 27.48 13.86 1.089
Enterprise Value (EV) 1 29.73 48.09 24.36 31.42 17.49 1.133
P/E ratio -5.48 x -6.98 x -4.4 x -9.16 x -11.9 x -0.74 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -21.6 x -7.62 x -5.4 x -10.4 x -4.64 x -1.7 x
EV / FCF 17.7 x -493 x -24.9 x -87.3 x -3.49 x 0.25 x
FCF Yield 5.64% -0.2% -4.02% -1.15% -28.6% 405%
Price to Book 10.5 x 51.6 x -71.7 x -13.7 x -26 x -0.55 x
Nbr of stocks (in thousands) 93,388 96,793 96,937 99,915 106,621 108,921
Reference price 2 0.3250 0.4800 0.2150 0.2750 0.1300 0.0100
Announcement Date 4/30/18 4/30/19 4/29/20 4/30/21 4/29/22 5/16/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -1.377 -6.313 -4.512 -3.022 -3.769 -0.6676
EBIT 1 -1.405 -6.365 -4.557 -3.067 -3.833 -0.6737
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -4.778 -6.586 -4.791 -3.078 -1.148 -0.4034
Net income 1 -4.778 -6.586 -4.74 -2.946 -1.128 -1.45
Net margin - - - - - -
EPS 2 -0.0593 -0.0688 -0.0489 -0.0300 -0.0109 -0.0136
Free Cash Flow 1 1.678 -0.0976 -0.9788 -0.36 -5.01 4.588
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/18 4/30/19 4/29/20 4/30/21 4/29/22 5/16/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - 1.63 3.52 3.94 3.63 0.04
Net Cash position 1 0.62 - - - - -
Leverage (Debt/EBITDA) - -0.2588 x -0.7797 x -1.305 x -0.9632 x -0.0652 x
Free Cash Flow 1 1.68 -0.1 -0.98 -0.36 -5.01 4.59
ROE (net income / shareholders' equity) -367% -348% -1,979% 225% 72.5% 25.4%
ROA (Net income/ Total Assets) -35.6% -106% -69.5% -42% -55.1% -13.5%
Assets 1 13.4 6.211 6.823 7.012 2.049 10.74
Book Value Per Share 2 0.0300 0.0100 -0 -0.0200 -0 -0.0200
Cash Flow per Share 2 0.0100 0 0 0 0 0
Capex 1 0.41 0.04 - 0 0 -
Capex / Sales - - - - - -
Announcement Date 4/30/18 4/30/19 4/29/20 4/30/21 4/29/22 5/16/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Uranium

1st Jan change Capi.
BIOCURE TECHNOLOGY INC. Stock Biocure Technology Inc.
-.--% 1.03M
URANIUM ENERGY CORP. Stock Uranium Energy Corp.
+6.72% 2.73B
CGN MINING COMPANY LIMITED Stock CGN Mining Company Limited
+19.19% 1.99B
YELLOW CAKE PLC Stock Yellow Cake plc
+8.33% 1.75B
BOSS ENERGY LIMITED Stock Boss Energy Limited
+26.05% 1.31B
CENTRUS ENERGY CORP. Stock Centrus Energy Corp.
-20.86% 687M
URANIUM ROYALTY CORP. Stock Uranium Royalty Corp.
-10.11% 282M
ELEVATE URANIUM LTD Stock Elevate Uranium Ltd
+14.61% 97.15M
GOVIEX URANIUM INC. Stock GoviEx Uranium Inc.
-43.33% 50.26M
Other Uranium
  1. Stock Market
  2. Equities
  3. CURE Stock
  4. Financials Biocure Technology Inc.